Regulatory Flexibility: BrainStorm’s Problematic NurOwn BLA May Be A Bridge Too Far For US FDA

 
• By Sue Sutter
Separate ways
The litany of problems with NurOwn may force the FDA to take a different path than it has with recently approved ALS drugs. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers